Volha V. Zhukouskaya

Volha V. Zhukouskaya

Auto-generated profile, based on publicly available information

Volha V. Zhukouskaya

Université de Paris Cité

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
FRFiammetta Romano
Fiammetta Romano
Giovanna MuscogiuriGiovanna Muscogiuri
Giovanna Muscogiuri
EBElea Di Benedetto
Elea Di Benedetto
VZVohla V.. V Zhukouskaya
Vohla V.. V Zhukouskaya
Luigi BarreaLuigi Barrea
Luigi Barrea
CSCarolina Di somma
Carolina Di somma
Background: Vitamin D exerts multiple pleiotropic effects beyond its role in calcium-phosphate metabolism. Growing evidence suggests an association between hypovitaminosis D and sleep disorders, thus increasing the interest in the role of this vitamin in the regulatory mechanisms of the sleep-wake cycle. Objective: The study aimed to explore and summarize the current knowledge about the role of vitamin D in sleep regulation and the impact of vitamin D deficiency on sleep disorders. Methods: The main regulatory mechanisms of vitamin D on sleep are explained in this study. The literature was scanned to identify clinical trials and correlation studies showing an association between vitamin D deficiency and sleep disorders. Results: Vitamin D receptors and the enzymes that control their activation and degradation are expressed in several areas of the brain involved in sleep regulation. Vitamin D is also involved in the pathways of production of Melatonin, the hormone involved in the regulation of human circadian rhythms and sleep. Furthermore, vitamin D can affect sleep indirectly through non-specific pain disorders, correlated with alterations in sleep quality, such as restless legs syndrome and obstructive sleep apnea syndrome. Conclusions: : Vitamin D has both a direct and an indirect role in the regulation of sleep. Although vitamin D deficiency has been associated to sleep disorders, there is still scant evidence to concretely support the role of vitamin D supplementation in the prevention or treatment of sleep disturbances; indeed, more intervention studies are needed to better clarify these aspects.

21 December 2022 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
JAJulia André
Julia André
VZVolha V. Zhukouskaya
Volha V. Zhukouskaya
ALAnne-Sophie Lambert
Anne-Sophie Lambert
JSJean-Pierre Salles
Jean-Pierre Salles
BMBrigitte Mignot
Brigitte Mignot
ALAgnès Linglart
Agnès Linglart
Background/aim: Despite optimal conventional treatment (oral phosphate supplements and active vitamin D analogs), about 40–50% of children with well-controlled X-linked hypophosphatemia (XLH) show linear growth failure, making them less likely to achieve an acceptable final height. Here, we studied the hypothesis that rhGH treatment improves final height in children with XLH and growth failure. Methods: Two cohorts of children with XLH were included in this retrospective longitudinal analysis: (1) a cohort treated with rhGH for short stature (n = 34) and (2) a cohort not treated with rhGH (n = 29). The mean duration of rhGH treatment was 4.4 ± 2.9 years. We collected the auxological parameters at various time points during follow-up until final height. Results: In rhGH-treated children, 2 years of rhGH therapy was associated with a significant increase in height from − 2.4 ± 0.9 to − 1.5 ± 0.7 SDS (p < 0.001). Their mean height at rhGH discontinuation was − 1.2 ± 0.9 SDS and at final height was − 1.3 ± 0.9 SDS corresponding to 165.5 ± 6.4 cm in boys and 155.5 ± 6.3 cm in girls. Notably, the two groups had similar final heights; i.e., the final height in children not treated with rhGH being − 1.2 ± 1.1 SDS (165.4 ± 6.8 cm in boys and 153.7 ± 7.8 cm in girls), p = 0.7. Conclusion: Treatment with rhGH permits to improve final height in children with XLH and growth failure, despite optimal conventional treatment. We propose therefore that rhGH therapy could be considered as an option for short stature in the context of XLH.

29 October 2021 in Science Advances
Verified
Journal Article
Open access
VZVolha V. Zhukouskaya
Volha V. Zhukouskaya
LJLouisa Jauze
Louisa Jauze
SCSéverine Charles
Séverine Charles
CLChristian Leborgne
Christian Leborgne
SHStéphane Hilliquin
Stéphane Hilliquin
GRGiuseppe Ronzitti
Giuseppe Ronzitti
A new therapeutic approach for the treatment of a skeletal disorder with AAVs bypasses bone resistance to gene transfer.

24 June 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
VZVolha V. Zhukouskaya
Volha V. Zhukouskaya
CBClaire Bardet
Claire Bardet
Editorial: Calcium: An Overview From Physiology to Pathological Mineralization

31 October 2024
Verified
Book Chapter
Closed access
PDF file
VZVolha V. Zhukouskaya
Volha V. Zhukouskaya
ALAgnès Linglart
Agnès Linglart
ALAnne-Sophie Lambert
Anne-Sophie Lambert

29 July 2023
Verified
Book Chapter
Closed access
PDF file
VZVolha V. Zhukouskaya
Volha V. Zhukouskaya
LALinglart Agnès
Linglart Agnès
LALambert Anne-Sophie
Lambert Anne-Sophie